Molineaux C J, Batzinger R P, Schmidt W, Bueding E
Teratog Carcinog Mutagen. 1980;1(2):129-39. doi: 10.1002/tcm.1770010202.
Previous studies have shown that a new antischistosomal drug, 4-isothiocyano-4'-nitro diphenylamine (CGP 4540, amoscanate), is not mutagenic in vitro, but the urines of animals treated with this drug have mutagenic activity. Mutagenicity can be eliminated by coadministration of some antibacterial agents and is not demonstrable in germ-free animals. The present study describes attempts to isolate and identify intestinal microorganisms responsible for the mutagenic activation of amoscanate. Streptococcus equinus, isolated from the intestinal tract of mice, as well as some other species of Streptococcus, were found to produce mutagenic activation of amoscanate when introduced into animals pretreated with antibacterial agents. Similarly, incubation of these strains with amoscanate in vitro resulted in the formation of a mutagenic product.
先前的研究表明，一种新型抗血吸虫药物4-异硫氰酸-4'-硝基二苯胺（CGP 4540，硝硫氰胺）在体外没有致突变性，但用该药物治疗的动物尿液具有致突变活性。同时给予某些抗菌剂可消除致突变性，且在无菌动物中未表现出致突变性。本研究描述了分离和鉴定负责硝硫氰胺诱变激活的肠道微生物的尝试。从小鼠肠道中分离出的马链球菌以及其他一些链球菌，当引入经抗菌剂预处理的动物体内时，会产生硝硫氰胺的诱变激活作用。同样，这些菌株与硝硫氰胺在体外孵育会导致形成诱变产物。
